Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus
Phase 1
Completed
- Conditions
- Systemic Lupus Erythematosus
- Registration Number
- NCT02194400
- Lead Sponsor
- Resolve Therapeutics
- Brief Summary
A one month multi-dose study will evaluate the safety and tolerability of 3 intravenous infusions of RSLV-132 in subjects with inactive to mild SLE.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
- Stable SLE with no anticipated change in medications for the next 60 days
Exclusion Criteria
- Other biologic drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 30 days
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
Clinical Research of West Florida
🇺🇸Clearwater, Florida, United States
West Michigan Rheumatology
🇺🇸Grand Rapids, Michigan, United States
Altoona Center for Clinical Research
🇺🇸Duncansville, Pennsylvania, United States
Metroplex Clinical Research
🇺🇸Dallas, Texas, United States
Clinical Research of West Florida🇺🇸Clearwater, Florida, United States